🚀 VC round data is live in beta, check it out!
Actuate Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Actuate Therapeutics and similar public comparables like Dogwood Therapeutics, Moberg Pharma, Kezar Life Sciences, Herantis Pharma and more.
Actuate Therapeutics Overview
About Actuate Therapeutics
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
Founded
2015
HQ
Employees
10
Website
Financials (LTM)
EV
$62M
Actuate Therapeutics Financials
Actuate Therapeutics reported last 12-month revenue of —.
In the same LTM period, Actuate Therapeutics generated had net loss of ($22M).
Revenue (LTM)
Actuate Therapeutics P&L
In the most recent fiscal year, Actuate Therapeutics reported revenue of — and EBITDA of ($22M).
Actuate Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($22M) | XXX | XXX | XXX |
| Net Profit | ($22M) | XXX | ($22M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Actuate Therapeutics Stock Performance
Actuate Therapeutics has current market cap of $55M, and enterprise value of $62M.
Market Cap Evolution
Actuate Therapeutics' stock price is $2.32.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $62M | $55M | 0.0% | XXX | XXX | XXX | $-0.94 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialActuate Therapeutics Valuation Multiples
Actuate Therapeutics trades at (2.8x) EV/EBITDA.
Actuate Therapeutics Financial Valuation Multiples
As of April 19, 2026, Actuate Therapeutics has market cap of $55M and EV of $62M.
Equity research analysts estimate Actuate Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Actuate Therapeutics has a P/E ratio of (2.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $55M | XXX | $55M | XXX | XXX | XXX |
| EV (current) | $62M | XXX | $62M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (2.8x) | XXX | XXX | XXX |
| EV/EBIT | (2.8x) | XXX | (2.7x) | XXX | XXX | XXX |
| P/E | (2.5x) | XXX | (2.5x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (3.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Actuate Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Actuate Therapeutics Margins & Growth Rates
Actuate Therapeutics' revenue in the last fiscal year grew by —.
Actuate Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $2.3M for the same period.
Actuate Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (19%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $2.3M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Actuate Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Actuate Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Dogwood Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Moberg Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Kezar Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Herantis Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Mereo BioPharma Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Actuate Therapeutics M&A Activity
Actuate Therapeutics acquired XXX companies to date.
Last acquisition by Actuate Therapeutics was on XXXXXXXX, XXXXX. Actuate Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Actuate Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialActuate Therapeutics Investment Activity
Actuate Therapeutics invested in XXX companies to date.
Actuate Therapeutics made its latest investment on XXXXXXXX, XXXXX. Actuate Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Actuate Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Actuate Therapeutics
| When was Actuate Therapeutics founded? | Actuate Therapeutics was founded in 2015. |
| Where is Actuate Therapeutics headquartered? | Actuate Therapeutics is headquartered in United States. |
| How many employees does Actuate Therapeutics have? | As of today, Actuate Therapeutics has over 10 employees. |
| Who is the CEO of Actuate Therapeutics? | Actuate Therapeutics' CEO is Daniel M. Schmitt. |
| Is Actuate Therapeutics publicly listed? | Yes, Actuate Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Actuate Therapeutics? | Actuate Therapeutics trades under ACTU ticker. |
| When did Actuate Therapeutics go public? | Actuate Therapeutics went public in 2024. |
| Who are competitors of Actuate Therapeutics? | Actuate Therapeutics main competitors are Dogwood Therapeutics, Moberg Pharma, Kezar Life Sciences, Herantis Pharma. |
| What is the current market cap of Actuate Therapeutics? | Actuate Therapeutics' current market cap is $55M. |
| Is Actuate Therapeutics profitable? | No, Actuate Therapeutics is not profitable. |
| What is the current net income of Actuate Therapeutics? | Actuate Therapeutics' last 12 months net income is ($22M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.